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Abstract
Whereas C-reactive protein (CRP), procalcitonin (PCT) and mid-regional pro-atrial natriuretic peptide (ANP) may be of use at the bed-
side in the management of adult patients with infectious disorders, their usefulness has not been established in the setting of acute
pyelonephritis. To assess the effectiveness of CRP, PCT and ANP measurements in guiding emergency physicians’ decisions whether to
admit to hospital patients with acute pyelonephritis, we conducted a multicentre, prospective, observational study in 12 emergency
departments in France; 582 consecutive patients were included. The reference standard for admission was deﬁned by experts’ advice
combined with necessity of admission or death during the 28-day follow-up. Baseline CRP, PCT and ANP were measured and their
accuracy in identifying the necessity of admission was analysed using area under curves (AUC) of receiver–operating characteristic
(ROC) plots. According to the reference standard, 126 (22%) patients required admission. ANP (AUC 0.75, 95% CI 0.69–0.80) and
PCT (AUC 0.75, 95% CI 0.71–0.80) more accurately predicted this than did CRP (AUC 0.69, 95% CI 0.64–0.74). The positive and nega-
tive likelihood ratios for each biomarker remained clinically irrelevant whatever the threshold. Our results did not support the use of
these markers to help physicians in deciding about admission of patients experiencing acute pyelonephritis in daily practice.
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Introduction
Acute pyelonephritis is an infection of the upper urinary
tract. Its estimated annual incidence is 20 cases per 10 000
population in the USA [1] for a cost of $2.14 billion [2].
Healthy, non-pregnant women with acute pyelonephritis
can be safely treated as out-patients if they do not have a
complicated infection or signs of systemic toxicity, are able
to take oral medications, and can be closely followed [3].
Whereas the course is usually favourable and the mortality
rate is low, 10% of patients visiting emergency departments
for acute pyelonephritis are ﬁnally hospitalized, accounting
for nearly 200 000 annual admissions in the USA [2]. Predict-
ing an unfavourable course in acute pyelonephritis is chal-
lenging in patients without obvious immediate complications.
Although severity factors have been identiﬁed [3,4], no pre-
diction rule has been developed to guide decisions concern-
ing admission of patients. Consequently, patients who could
safely have been treated as out-patients are often admitted
[5].
The use of biomarkers to assess patients’ illness severity
has been suggested in the setting of several infections. The
serum concentration of C-reactive protein (CRP) has been
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widely used in acute infectious disorders. The CRP level may
contribute to diagnosis, severity assessment and treatment
follow-up of infection, although controversial results have
been published [6–8]. Procalcitonin (PCT) is a potent marker
to predict poor prognosis in systemic infections [9,10]. Mid-
regional pro-atrial natriuretic peptide (ANP) is an emergent
biomarker in sepsis that might be even more accurate than
PCT in predicting death [11]. The use of these markers has
been advocated to guide risk-assessment and therapy at the
bedside in several infectious diseases.
Previous results have been encouraging as PCT was effec-
tive in aiding diagnosis and risk-stratiﬁcation [12,13] in chil-
dren with upper urinary tract infection. However, even
though the level of PCT is commonly increased in acute
pyelonephritis, a study has reported its ineffectiveness in
detecting adult emergency patients who will suffer an unfa-
vourable course [14].
We therefore conducted a study to assess whether initial
blood concentrations of CRP, PCT and ANP could guide
emergency physicians’ decisions whether to admit patients
presenting to emergency departments with acute pyelone-
phritis.
Methods
Objective
Our objective was to assess the overall accuracy of CRP,
PCT and ANP levels in discriminating between reference
standard in-patients and out-patients.
Setting
We conducted a multicentre, prospective, observational
study in 12 French emergency departments, entitled ‘The
Biomarkers In Sepsis (BIS) Study’.
The study protocol and procedures complied with the
principles of the Declaration of Helsinki. The institutional
review board for the protection of human subjects of Cochin
Port-Royal (Paris, France) approved the study protocol and
patient informed consent procedures. All enrolled patients
provided written informed consent for participation.
Study population
Standardized screening forms were used in each centre to
help identify eligible patients. We enrolled all consecutive
consenting adults (‡18 years old) with a diagnosis of acute
pyelonephritis. Diagnosis of acute pyelonephritis was based
on the following criteria: temperature of ‡38.5C, positive
dipstick test for nitrite reaction and urine leucocyte activity,
subsequently conﬁrmed by urinalysis with >105 white blood
cells per millilitre, acute onset of at least one of the follow-
ing signs or symptoms: dysuria, nausea, ﬂank pain, costover-
tebral angle tenderness. Patients with the following
conditions were excluded : history of manual or instrumental
urological examination within 1 month before the present
episode of acute pyelonephritis; history of previous antibiotic
treatment, deﬁned as antibiotic use for at least 3 days during
the past month; presence of an indwelling urinary catheter;
presence of previous structural or functional abnormalities
(including bladder diverticula, cystocoeles, urethral strictures,
congenital abnormalities, and renal cysts, as well as functional
abnormalities, such as neurogenic bladder and vesicoureteral
reﬂux, kidney failure deﬁned as a creatinine level
>130 mmol/L); lumbar or abdominal tenderness; i.e. tender-
ness to pressure either on the lumbar region or on the
abdomen? pregnancy, human immunodeﬁciency virus infec-
tion or being otherwise immunocompromised (active neo-
plasm, immunosuppressive therapy, prednisone >15 mg/day
or equivalent); septic shock [15]; palliative care (precluding
admission to an ICU); anticipated barriers to complete
follow-up data collection (e.g. homelessness, psychiatric
disorder).
Baseline data and emergency department management
Patient management was based on current recommended
practice guidelines [3]. The attending physician made the
symptom-based decision and proceeded to baseline data col-
lection through patient interviews and standardized review
of medical records. Baseline data consisted of demographic
information (age, gender), coexisting illnesses, symptoms, and
clinical ﬁndings as well as laboratory tests, whenever per-
formed (i.e. white blood cell count, haematocrit, blood urea
nitrogen, glucose, sodium). Except for the CRP, PCT and
ANP measurements that were required by the study proto-
col, laboratory and imaging studies were performed at the
attending physicians’ discretion. The attending emergency
physicians’ rationale for the patient hospitalization decision
was also recorded, and they declared whether the decision
to admit the patient was exclusively based on the medical
condition, or on social or organizational constraints in addi-
tion. The study investigators were not directly involved in
the care of patients enrolled in the study and did not partici-
pate in patient management, either their treatment or the
hospitalization decision. Attending physicians were blinded to
the CRP, PCT and ANP levels.
C-reactive protein, procalcitonin and mid-regional pro-atrial
natriuretic peptide measurement.
Blood samples were collected in sodium heparin-treated
tubes, centrifuged, and stored at )20C within 4 h of patient
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enrolment. Subsequently all study samples were safely stored
in our central laboratory (Department of Biochemistry,
Hoˆpital Cochin) until the completion of all study enrolments
and 28-day follow-up for all enrolled patients. For quality
control, all study biochemical marker (CRP, PCT and ANP)
levels were measured in duplicate during a single session and
the laboratory measurement process complied with French
quality standards for medical laboratories [15]. CRP mea-
surement was performed using an immunoturbidimetric assay
(Modular analyser; Roche Diagnostics, Basel, Switzerland).
PCT and ANP (epitopes covering amino acids 53–90) con-
centrations were analysed by use of a sandwich immunoassay
and Time Resolved Ampliﬁed Cryptate Emission (TRACE)
measurement (Kryptor; Brahms Diagnostica, Hennigsdorf,
Germany).
Follow-up and reference Standard
Subsequent admission and mortality data were obtained at
the end of the 28-day follow-up period by telephone inter-
views with the patient, a relative, or the family practitioner.
On the basis of patients’ baseline data collected on standard-
ized case report forms, an expert committee consisting of
three experts in infectious diseases and emergency medicine
independently determined necessity of the admission at pre-
sentation in the emergency department for each participant.
Experts were blinded to CRP, PCT and ANP levels, and to
the emergency physician’s hospitalization decision. In case of
disagreement that could not be resolved by discussion, the
ﬁnal decision was based on agreement of any two experts.
For the study purpose, we considered as adverse medical
outcomes any event (subsequent admission after initial dis-
charge, readmission after hospitalization, death) occurring
within 28 days of initial emergency department presentation.
We deﬁned as ‘reference standard in-patients’ the patients
who were judged by the expert committee to require hospi-
talization or those who experienced adverse medical out-
come during study follow-up. The remaining patients were
designated ‘reference standard out-patients’.
Statistical analysis
The sample size calculation was based on the ability to
detect a speciﬁcity for ANP of 0.90. To achieve the precision
of 0.05 for speciﬁcity, we needed to include at least 422
patients (with 140 patients hospitalized). Baseline and follow-
up characteristics were described by means and standard
deviations (SD) or by median and interquartile range (IQR)
for continuous variables, as appropriate, and by percentages
for categorical variables. We performed v2 statistics or Fish-
er’s exact tests when appropriate for qualitative variables,
and the Wilcoxon/Mann–Whitney test for continuous vari-
ables with skewed distributions to compare baseline patient
characteristics and study outcomes.
We referred to the STAndards for the Reporting of Diag-
nostic Accuracy (STARD) recommendations for analysis of
the results [16]. We used the area under receiver–operator
characteristic curves (AUC) to assess the overall discrimina-
tory power of CRP, PCT and ANP in predicting the refer-
ence standard for admission. The AUC and its 95% CIs were
estimated for each biomarker and compared by a non-para-
metric method.
We estimated CRP, PCT and ANP cut-off values yielding
95% sensitivity and 95% speciﬁcity values, and subsequently
estimated the threshold maximizing the sum of sensitivity
and speciﬁcity (Youden index). Sensitivity, speciﬁcity and
positive and negative predictive values were calculated for
each cut-off value of CRP, PCT and ANP. We also calculated
likelihood ratios (LR) as a measure of the extent to which
the pre-test odds were altered by the test results; low LR
(<0.1) and high LR (>10) are considered useful in ruling out
and conﬁrming decisions, respectively [17,18].
All tests were two-sided, and p-values <0.05 were consid-
ered to denote statistical signiﬁcance. All statistical analyses
were performed using SAS software V9.1 (SAS Institute,
Cary, NC, USA).
Results
Study patients’ characteristics.
The inclusion period extended from November 2004 to
November 2007. In total, 785 patients visiting the emergency
department were initially identiﬁed with a diagnosis of acute
pyelonephritis and consequently eligible for the study. Of
these, 87 could not be included because of protocol violation
and 29 were excluded because of incomplete data. Conse-
quently, 669 patients had complete data at baseline. The
28-day follow-up was completed for 582 participants, corre-
sponding to the study population (Fig. 1). Attending physicians
decided to admit 153 patients; among these, four refused
admission in spite of the attending physician’s advice; among
the 149 remaining patients, 13 were admitted because of social
and organizational constraints.
Baseline patient characteristics are reported in Table 1. As
expected, most patients were young healthy women.
Signiﬁcant underlying disorders were noticed in 50 patients,
distributed as follows: 25 congestive heart failure, 21 diabe-
tes mellitus, seven chronic renal failure and ten other. The
baseline characteristics of patients who were not enrolled
did not differ from those of the study population (data not
shown). Microbiological results were positive in 478 urines
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and 48 blood cultures, representing 489 patients distributed
as follows: 458 Escherichia coli, 21 other Gram-negative bacilli,
16 Staphylococcus spp., ten other Gram-positive cocci and 16
miscellaneous.
Study outcomes
The experts’ committee fully agreed on the decision con-
cerning 411 (71%) patients. Among the 473 patients judged
suitable for out-patient management by the experts’ com-
mittee, 17 (3.6%) required admission by day 28. Thus,
according to reference standard, 126 (21.6%) patients
should have been admitted and 456 (78.4%) should have
been discharged. All patients survived to the end of the
follow-up period.
Levels of CRP, PCT and ANP were statistically higher in
reference standard in-patients than in reference standard
out-patients (p <0.01 for each biomarker, Table 1). In order
to determine the performance of the different tests, we cal-
culated AUC for each biomarker compared with the refer-
ence standard. Values were 0.75 (0.71–0.80), 0.69 (0.64–
0.74) and 0.75 (0.69–0.80) for PCT, CRP and ANP, respec-
tively (Fig. 2). Performance of ANP and PCT was similar
(p 0.77). CRP did not differ signiﬁcantly from ANP (p 0.07),
whereas its difference from PCT was statistically signiﬁcant
(p <0.01). In an analysis assuming that patients lost to
follow-up were not admitted, the AUC for each biomarker
remained essentially unchanged (data not shown).
Performance characteristics were tested for various cut-
offs of CRP, PCT and ANP. As shown in Table 2, likelihood
ratios were not clinically relevant whatever the biomarker or
threshold. As a result, emergency physicians more accurately
classiﬁed patients according to reference standard than PCT
and ANP (Table 3).
Discussion
In this study, we evaluated whether CRP, PCT and ANP
allowed prediction of the requirement for admission in adult
pyelonephritis. We observed that the performance of ANP
and PCT was similar, whereas CRP measurement poorly
predicted outcome. However, the values of the likelihood
ratios indicated that none of these three markers could
reliably help physicians in their decision-making process.
Biomarkers can be useful in the management of infectious
disorders. For example, it has been suggested that PCT is a
Excluded  (n = 87)
Did not meet inclusion criteria  (n = 42)
Refuse d to participate (n = 45)
Incomplete data  (n = 29)
Biomarker values missing (n = 28)
Clinical data missing   (n = 1)
Included (n =  698)
Assessed for eligibility (n = 785)
With follow-up at day 28 (n = 582) 
Admission by 
Readmitted at day 28
Discharge by 
Admission at day 28 
Included with complete data (n = 669)
ED physician advice Experts advice* 
Admitted 178 120
Discharged 491 549
Without follow-up at day 28 (n = 87)
Lost to follow-up  (n = 84)
Refused to reply   (n = 3)
Reference standard  
for hospitalization 
 Admission (n = 126) 
 Discharge  (n = 456)
ED physician advice 
n = 153
n = 13
ED physician advice 
n = 429
n = 14
Expert advice*
n = 109
n = 10
Expert advice* 
n = 473
n = 17 FIG. 1. Flow chart of patients with acute
pyelonephritis assessed for eligibility.
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valuable marker in indicating a bacterial cause and severity of
acute infections in the emergency department [10]. How-
ever, PCT values in septic patients with adverse outcomes
may widely overlap those associated with an uncomplicated
course. Whereas the PCT value can be reliable for diagnosis
and assessment of severity of pyelonephritis in paediatric
patients [13], it has been previously reported that PCT
showed good speciﬁcity but was poorly sensitive in detecting
acute pyelonephritis in an adult population [19]. A monocentre
study reported that PCT measurements did not signiﬁcantly
differ between patients with complicated and uncomplicated
acute pyelonephritis. The PCT level did not predict adverse
outcomes (AUC 0.67, 95% CI 0.51–0.86) [14]. The value of
CRP has been debated and most authors now consider that
it should not be used to manage acute pyelonephritis. An
increased level of CRP was sensitive but poorly speciﬁc in
assessing severity in adults with urinary tract infection
[19,20]. CRP values did not correlate with radiological
extent of parenchymal damage [21]. To our knowledge, ANP
has not been speciﬁcally studied in the setting of urinary
tract infection. This promising marker may help predict the
prognosis even more accurately than PCT. The results
reported here, however, do not support the use of ANP to
determine the admission requirement for adults visiting the
emergency department with acute pyelonephritis.
To our knowledge, we report here the largest study that
has assessed the effectiveness of biomarkers in this role. How-
ever, we acknowledge that this study has several limitations.
We excluded patients who obviously needed admission
because of severe clinical presentation, mechanical complica-
tion, and immunosuppression. Therefore, we cannot exclude
the possibility that biomarkers may be useful in these patient
categories. However, the aim of this study was to determine
whether CRP, PCT and ANP could help physicians come to a
TABLE 1. Baseline characteristics of the study population and comparison of study groups according to reference standard for
admission
Reference standard hospital admission decisiona
Discharge (n = 456) Admission (n = 126) Total (n = 582) p-value*
Demographic factors
Male sex, n (%) 15 (3.3) 25 (19.8) 40 (6.9) <0.01
Age (years), mean (SD) 34.1 (14.0) 55.7 (23.7) 38.8 (18.8) <0.01
Clinical characteristics
Heart rate (bpm), median [IQR] 100 [86; 110] 101 [87; 119] 100 [86; 112] 0.07
Systolic blood pressure (mmHg), median [IQR] 120 [110; 131] 123 [109; 138] 120 [109; 132] 0.13
Temperature (C), median [IQR] 37.9 [37.0; 38.7] 38.4 [37.8; 39.2] 38.0 [37.1; 38.8] <0.01
Coexisting conditions
Diabetes mellitus, n (%) 1 (0.2) 20 (15.9) 21 (3.6) <0.01
Liver disease, n (%) 2 (0.4) 2 (1.6) 4 (0.7) 0.20
Heart disease, n (%) 4 (0.9) 21 (16.7) 25 (4.3) <0.01
Cerebrovascular disease, n (%) 0 (0.0) 6 (4.8) 6 (1.0) <0.01
Renal disease, n (%) 2 (0.4) 5 (4.0) 7 (1.2) <0.01
Laboratory ﬁndings
Leucocytes (/lL), median [IQR] 11.6 [9.2; 14.0] 12.6 [9.7;16.3] 11.7 [9.3; 14.6] 0.04
Haematocrit (%), median [IQR] 37.6 [36.0;39.8] 36.8 [34.6;40.1] 37.5 [35.6; 39.9] 0.07
Platelets (g/lL), median [IQR] 242.0 [204.0; 290.0] 218.0 [172.0;259.0] 239.0 [196.0; 280.5] <0.01
Sodium (mmol/L), median [IQR] 138.0 [136.0;140.0] 137.0 [135.0;139.0] 138.0 [136.0; 140.0] <0.01
Urea (mmol/L), median [IQR] 3.7 [2.9; 4.7] 4.8 [3.7; 8.4] 3.9 [3.0; 5.0] <0.01
Biomarkers
CRP (mg/L), median [IQR] 64.2 [19.9;146.3] 149.7 [60.4;233.4] 76.7 [27.7;165.1] <0.01
PCT (ng/mL), median [IQR] 0.1 [0.1;0.5] 1.2 [0.2;3.3] 0.2 [0.1;0.8] <0.01
ANP (pmol/L), median [IQR] 61.2 [48.8;77.1] 99.8 [67.3;191.9] 65.0 [49.7;87.0] <0.01
Values are expressed as number (%), mean (standard deviation, SD) and median [interquartile range, IQR]. CRP, C-reactive protein; PCT, procalcitonin; ANP, mid regional
pro-natriuretic peptide.
aThe reference standard for hospital admission decision referred to experts’ committee advice corrected by admission requirement during the 28-day follow-up.
*Comparisons between groups were performed using the v2 test or Fisher’s Exact test for qualitative variables and the Wilcoxon/Mann–Whitney test for the Student’s t-test
or quantitative variables.
AUC (95 CI)
p-value < 0.01 
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FIG. 2. Receiver–operating characteristics (ROC) curves of biomar-
kers with respect to reference standard for admission. C-reactive
protein (CRP): light grey; procalcitonin (PCT): dark grey; mid regio-
nal pro-atrial natriuretic peptide (ANP): black.
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better judgement of the need for admission in acute pyelone-
phritis. Furthermore, the results of this adult study can not be
applied in a paediatric setting, where the relevance of biomar-
kers clearly differs. Additionally, the quality of our reference
standard is debatable. Despite major recent advances in clinical
medical research, no widely accepted reference standard is
currently available. We consequently employed a method
repeatedly used in previous studies in this ﬁeld, i.e. the advice
of a blinded independent experts’ committee combined with
adverse medical events within a 28-day follow-up. To avoid
bias, our reference standard committee was blinded to the
clinical context (emergency physicians’ decision and 28-day
outcome) and the biomarker measurements.
Our results indicate that PCT and ANP more efﬁciently
predicted admission necessity than did CRP. However,
these biomarkers were not clinically relevant in determining
the site of care. To conclude, our results did not support the
use of biomarkers to guide site of care in adult pyelonephritis.
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TABLE 2. Ability of mid-regional atrial natriuretic peptide (ANP), C-reactive protein (CRP) and procalcitonin (PCT) to pre-
dict admission for medical purpose according to reference standard
Cut-off
Sensitivity
[95% CI]
Speciﬁcity
[95% CI]
Positive predictive
value [95% CI]
Negative predictive
value [95% CI]
Positive likelihood
ratio [95% CI]
Negative likelihood
ratio [95% CI]
ANP (pmol/L)
37 94.4 [90.4; 98.4] 7.7 [5.2; 10.1] 0.22 [0.19; 0.26] 0.83 [0.72; 0.95] 1.02 [0.97; 2.25] 0.72 [0.33; 1.59]
96 (Youden index) 53.2 [44.5; 61.9] 88.2 [85.2; 91.1] 0.55 [0.47; 0.64] 0.87 [0.84; 0.90] 4.49 [3.33; 5.42] 0.53 [0.44; 0.64]
122 38.9 [30.4; 47.4] 95.0 [92.9; 97.0] 0.68 [0.57; 0.79] 0.85 [0.82; 0.88] 7.71 [4.89; 8.88] 0.64 [0.56; 0.74]
CRP (mg/L)
21 95.2 [91.5; 99.0] 26.3 [22.3; 30.4] 0.26 [0.22; 0.30] 0.95 [0.92; 0.99] 1.29 [1.21; 2.86] 0.18 [0.08; 0.40]
93 (Youden index) 67.5 [59.3; 75.6] 62.3 [57.8; 66.7] 0.33 [0.27; 0.39] 0.87 [0.84; 0.91] 1.79 [1.51; 2.32] 0.52 [0.40; 0.68]
261 17.5 [10.8; 24.1] 95.0 [92.9; 97.0] 0.49 [0.34; 0.63] 0.81 [0.77; 0.84] 3.46 [2.00; 3.76] 0.87 [0.80; 0.94]
PCT (ng/mL)
0.06 96.0 [92.6; 99.4] 22.4 [18.5; 26.2] 0.25 [0.22; 0.29] 0.95 [0.91; 0.99] 1.24 [1.16; 2.97] 0.18 [0.07; 0.43]
0.17 (Youden index) 82.5 [75.9; 89.2] 56.4 [51.8; 60.9] 0.34 [0.29; 0.40] 0.92 [0.89; 0.95] 1.89 [1.66; 2.79] 0.31 [0.21; 0.46]
5.39 16.7 [10.2; 23.2] 95 [92.9; 97.0] 0.48 [0.33; 0.62] 0.80 [0.77; 0.84] 3.3 [1.89; 3.58] 0.88 [0.81; 0.95]
Youden Index = Sensitivity + Speciﬁcity – 1.
TABLE 3. Distribution of patients
admitted and discharged according
to emergency department (ED)
physicians’ advice and biomarker
cut-offs compared with reference
standard
Reference standard
Admission (n = 126) Discharged (n = 456) Total (n = 582)
PCT (ng/mL)
0.17, Youden index 16 (13%) 356 (78%) 372 (64%)
5.39, 95% speciﬁcity 62 (49%) 233 (51%) 295 (51%)
ANP (pmol/L)
96, Youden index 33 (26%) 354 (78%) 387 (66%)
122, 95% speciﬁcity 44 (35%) 337 (74%) 381 (65%)
ED physicians advice 67 (53%) 370 (81%) 437 (75%)
Results are presented as number (%). PCT, procalcitonin; ANP, mid-regional pro-atrial natriuretic peptide.
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